Trials / Completed
CompletedNCT02040415
Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients
A Multicenter, Randomized, Double-blinded, Parallel, Active-controlled, Phase Lll Clinical Trial to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 242 (actual)
- Sponsor
- Daewon Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this clinical study is to determine whether or not DW-1030 is not inferior to eperisone HCl in efficacy and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DW-1030(eperisone HCl) 75mg | |
| DRUG | Myonal Tab.(eperisone HCl) 50mg | |
| DRUG | Placebo drug of DW-1030 | |
| DRUG | Placebo drug of Myonal Tab. |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2014-07-01
- First posted
- 2014-01-20
- Last updated
- 2016-10-12
Source: ClinicalTrials.gov record NCT02040415. Inclusion in this directory is not an endorsement.